Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 904 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Comparator 1 Clear all
Completed Phase 1Phase 2 Interventional Results available

Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

NCT00345384
View directory record Official record
Conditions
Post-operative Pain, Respiratory Depression
Interventions
Dexmedetomidine, Placebo (Normal Saline)
Drug · Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Single-Session Intervention Targeting Self-Injurious Behavior in Adolescents

NCT04498143
View directory record Official record
Conditions
Nonsuicidal Self Injury, Self Hatred, Suicidal Thoughts, Suicide Attempts
Interventions
Project SAVE ("Stop Adolescent Violence Everywhere") SSI, Active Comparator: Supportive Therapy ("Share Your Feelings") SSI
Other
Lead sponsor
University of Denver
Other
Eligibility
13 Years to 16 Years
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis

NCT02137226
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
BI 695501, US-licensed Humira®
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
645 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
63
States / cities
Anniston, Alabama • Birmingham, Alabama • Glendale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Implementation Science Approach to Enhancing Depression Treatment in Collaborative Depression Care Settings ( DepCare )

NCT05085886
View directory record Official record
Conditions
Depressive Symptoms
Interventions
DepCare, Enhanced Usual Care
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 3, 2026, 9:27 AM EDT
Active, not recruiting Phase 2 Interventional

4D-150 in Patients With Diabetic Macular Edema

NCT05930561
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
4D-150 IVT, Aflibercept IVT
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Not applicable Interventional

Creating Live Interactions to Mitigate Barriers

NCT03317769
View directory record Official record
Conditions
Schizophrenia
Interventions
Computerized Plasticity-Based Adaptive Cognitive Training, Commercially available computerized training, Optimized social skills training, Unstructured support group sessions
Other
Lead sponsor
Posit Science Corporation
Industry
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stress Reduction Training to Improve Sleep Quality, Stress Physiology & Cardiovascular Disease (CVD) Risk Markers

NCT01343810
View directory record Official record
Conditions
Stress, Psychological, Sleep, Inflammation, Cardiovascular Diseases
Interventions
Mindfulness-Based Stress Reduction (MBSR)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 9, 2014 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 3, 2026, 9:27 AM EDT
Recruiting Phase 3 Interventional

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

NCT07247188
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 2Phase 3 Interventional

Cranberry Juice for Treatment of Urinary Tract Infections

NCT00093054
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Cranberry juice, Placebo cranberry juice
Drug · Dietary Supplement
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 3, 2026, 9:27 AM EDT
Terminated Not applicable Interventional Results available

Intercostal Cryoneurolysis Following Traumatic Rib Fractures

NCT03917823
View directory record Official record
Conditions
Rib Fractures
Interventions
Cryoneurolysis, Sham comparator
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of Sialic Acid Tables in Patients With Hereditary Inclusion Body Myopathy (HIBM)

NCT01359319
View directory record Official record
Conditions
Hereditary Inclusion Body Myopathy (HIBM)
Interventions
Sialic Acid Extended Release (SA-ER) Tablets, Sialic Acid Extended Release (SA-ER) Tables
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Costa Mesa, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2012 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

NCT01392326
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (75 mg), Secukinumab (150 mg), Placebo Comparator
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

NCT00455325
View directory record Official record
Conditions
Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions
Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Not applicable Interventional

A Study to Evaluate the Effects of a Fiber Supplement on Gut Health

NCT07755735
View directory record Official record
Conditions
Gut Health, Bloating, Irregular Bowel Movements, Gastrointestinal Symptoms
Interventions
Active Supplement, Placebo Comparator
Dietary Supplement
Lead sponsor
Belli Welli Inc.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

NCT03945292
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Fazisiran Injection, Placebo
Drug · Other
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Financial Incentives to Exercise for Adolescents

NCT01848353
View directory record Official record
Conditions
Insulin Resistance, Obesity, Sedentary Lifestyle
Interventions
Exercise training
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
11 Years to 20 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
Hugo, Oklahoma • Talihina, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 3, 2026, 9:27 AM EDT
Recruiting Early Phase 1 Interventional

Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension

NCT06482853
View directory record Official record
Conditions
Obesity, Hypertension
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity

NCT03307837
View directory record Official record
Conditions
Hallux Valgus Deformity
Interventions
CA-008, Placebo
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)

NCT02452372
View directory record Official record
Conditions
Acute Intermittent Porphyria
Interventions
givosiran (ALN-AS1), Sterile Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 1Phase 2 Interventional

Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

NCT06162728
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Briquilimab, Placebo
Drug · Other
Lead sponsor
Jasper Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 3, 2026, 9:27 AM EDT
Terminated Phase 3 Interventional Results available

D-cycloserine in the Management of Chemotherapy-Induced Peripheral Neuropathic Pain

NCT00301080
View directory record Official record
Conditions
Neurotoxicity, Pain, Breast Cancer
Interventions
D-cycloserine, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 1, 2013 · Synced Sep 3, 2026, 9:27 AM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

NCT00034580
View directory record Official record
Conditions
Bipolar Disorder
Interventions
olanzapine, risperidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
21
States / cities
Berkley, California • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Sep 3, 2026, 9:27 AM EDT